ClinicalTrials.gg
TerminatedNCT03295396Updated Jul 28, 2025Results posted

ONC201 in Adults With Recurrent H3 K27M-mutant Glioma

A Phase 2 interventional study of Dordaviprone (ONC201) in Glioma, sponsored by Jazz Pharmaceuticals. Terminated at 9 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-28.

Sponsored by Jazz Pharmaceuticals · Phase 2, Interventional, and Treatment

Why this study was terminated
The Sponsor terminated the study to prioritize enrollment in a randomized Phase 3 trial of ONC201 in an earlier setting. This decision was unrelated to any safety concerns with dordaviprone (ONC201).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
73
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 851 studies in Glioma with a site in United States — 142 open to participants now, 229 under way, 6 of them phase 3. Glioma · United States.

Enrollment
135th of 737
73 · median 30
Started
2017
with 43 others
Phase 2
227 of 851
21 open now
Registered
521st of 851
by date

Among the 851 studies in Glioma with a site in United States, this one is the 135th largest by enrollment of the 737 interventional ones that give a count, is one of 44 that started in 2017, is one of 227 in phase 2, and was the 521st registered.

Glioma

1,454 studies on the registry are indexed under Glioma; 350 are open to participants now.

Browse Glioma studies →

Open to participants now

142 of the 851 studies in Glioma with a site in United States are open now. Recruiting first, the newest first:

137 more — sign in →

All 142 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 267 Glioma studies recruiting now, 165 (62%) set no upper age limit and 56 (21%) stop at 75 or younger; 62 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 851 studies in Glioma with a site in United States, or all of them as a file.
02

Study summary

This was a Phase 2, open-label, 2-arm study of dordaviprone (ONC201) in patients with recurrent H3 K27M- mutant glioma.

The primary assessment of dordaviprone (ONC201) involved evaluating its anti-tumor activity through the overall response rate according to the Response Assessment in Neuro-Oncology (RANO) criteria for high-grade glioma (HGG).

Read the detailed description

This study included 2 arms:

  • Arm A included patients with recurrent H3 K27M-mutant glioma.
  • Arm B included patients with recurrent H3 K27M-mutant glioma, but excluded patients with the following:

    • Primary malignant lesion located in the pons or spinal cord.
    • Atypical non-astrocytic histologies such as ependymoma, ganglioma and pleomorphic xanthoastrocytoma, or pilocytic astrocytoma and subependymal giant cell astrocytoma (SEGA).
    • Prior bevacizumab treatment of >4 doses of >7.5 mg/kg

Patients received dordaviprone (ONC201) 625 mg once weekly.

The primary assessment of dordaviprone (ONC201) involved evaluating its anti-tumor activity through the overall response rate according to the Response Assessment in Neuro-Oncology (RANO) criteria for high-grade glioma (HGG). Safety was also assessed, with evaluations including the reporting of adverse events, as well as measurements of vital signs and clinical laboratory results.

This study was terminated by an administrative protocol amendment (17 January 2023). The decision to terminate the study was not related to any safety concerns with dordaviprone (ONC201). Before the study was terminated, a total of 73 patients were enrolled and received at least 1 dose of dordaviprone (ONC201).

03

Conditions studied

  • Glioma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Had confirmed diagnosis of high-grade glioma (HGG) in any tumor sample and presence of histone H3 K27M mutation detected in a Clinical Laboratory Improvement Amendment (CLIA) certified laboratory by immunohistochemistry or DNA sequencing test on any glioma tumor sample.
  2. Had unequivocal evidence of progressive disease on contrast-enhanced brain computed tomography (CT) or magnetic resonance imaging (MRI) as defined by Response Assessment in Neuro-Oncology (RANO)-HGG criteria, or have documented recurrent glioma on diagnostic .
  3. Had by RANO-HGG criteria.
  4. Patients must have had previous therapy with at least radiotherapy.
  5. Had no more than two prior episodes of recurrence from radiotherapy and/or chemotherapy. Use of bevacizumab solely for treatment of radiation necrosis, pseudoprogression, or treatment effect was not considered a recurrence.
  6. Had an interval of at least 90 days from the completion of radiotherapy to the first dose of dordaviprone (ONC201). If patients were within 90 days of radiotherapy, they may have still been eligible if they met one or more of the following criteria.

    1. Progressive tumor is outside the original high-dose radiotherapy target volume as determined by the treating investigator, or
    2. Histologic confirmation of tumor through biopsy or resection, or
    3. Nuclear medicine imaging, magnetic resonance (MR) spectroscopy, or MR perfusion imaging consistent with true progressive disease, rather than pseudoprogression or radiation necrosis obtained within 28 days of registration.
  7. From the projected start of scheduled study treatment, the following time periods must have had elapsed: 5 half-lives from any agent, 4 weeks from cytotoxic therapy (except 23 days for temozolomide and 6 weeks from nitrosoureas), 6 weeks from antibodies, or 4 weeks (or 5 half-lives, whichever is shorter) from other anti-tumor therapies.
  8. All adverse events Grade >1 related to prior therapies (chemotherapy, radiotherapy, and/or surgery) must have been resolved to Grade 1 or baseline, except for alopecia and sensory neuropathy Grade ≤2, or other Grade ≤2 not constituting a safety risk based on investigator's judgment, are acceptable.
  9. Were male or female aged ≥18 years.
  10. Had a Performance Status (KPS) ≥60.
  11. Had adequate organ and marrow function as defined below, all screening labs should be performed within 14 days of treatment initiation:

    • leukocytes ≥ 3,000/mcL
    • ≥ 1,500/mcL
    • ≥ 75,000/mcL
    • > 8.0 mg/dL
    • total ≤ 2.0 × (ULN)
    • (AST) [SGOT]/alanine aminotransferase (ALT) [SGPT] ≤ 2.5 × ULN
    • creatinine ≤ULN OR ≥60 mL/min/1.73 m2 for patients with creatinine levels above normal.
  12. Had contrast-enhanced head CT or brain MRI and entire spine MRI within 14 days prior to start of study drug.
  13. dose must have been stable or decreasing for at least 3 days prior to the baseline CT or MRI scan.
  14. Women of (WOCBP) and men must have agreed to use adequate prior to study entry and for the duration of study participation and for 30 days after the last dose of therapy. Highly effective contraceptive measures include: stable use of oral contraceptives such as combined estrogen and progestogen and progestogen only hormonal contraception or other prescription pharmaceutical contraceptives for 2 or more menstrual cycles prior to screening; intrauterine device [IUD]; intrauterine hormone-releasing system (IUS); bilateral tubal ligation; vasectomy and sexual abstinence.

    1. WOCBP must have had a negative serum or urine pregnancy test within 28 days of initiation of dosing.
    2. Contraception was not required for men with documented vasectomy.
    3. women must have been amenorrheic for at least 12 months in order not to be considered of childbearing potential.
    4. Pregnancy testing and contraception were not required for women with documented hysterectomy or tubal ligation.
  15. Had availability of a paraffin-embedded or frozen tumor-tissue block with a minimum of 1 cm2 of tumor surface area, or 20 unstained slides from the tumor tissue specimen if a tumor block cannot be submitted. If a patient has had only a stereotactic biopsy, then 5 unstained slides may be accepted with prior approval from the Sponsor, however all efforts must be made to obtain as close to 20 slides as possible.
  16. Had the ability to be able to swallow and retain orally administered medication
  17. Had the ability to understand and the willingness to sign a written document. Only patients who had capacity to consent were enrolled in the study.

Exclusion criteria

Exclusion Criteria:

  1. Arm B: Had a primary malignant lesion located in the pons or spinal cord.
  2. Arm B: Had atypical non-astrocytic histologies such as ependymoma, ganglioma and pleomorphic xanthoastrocytoma, or pilocytic astrocytoma and subependymal giant cell astrocytoma (SEGA).
  3. Arm B: Had prior bevacizumab treatment of >4 doses of >7.5 mg/kg
  4. Had a history of allergic reactions attributed to compounds of similar chemical or biologic composition to dordaviprone (ONC201) or its .
  5. Had current or planned participation in a study of an agent or using an investigational device.
  6. Had presence of diffuse or evidence of cerebrospinal fluid (CSF) dissemination.
  7. Had uncontrolled intercurrent illness including, but not limited to, ongoing or active infection or psychiatric illness/social situations that would limit compliance with study requirements.
  8. Had an active infection requiring systemic therapy.
  9. Were pregnant and/or breastfeeding women or unable to maintain use of while on study and for 30 days after the last dose of study drug. Dordaviprone (ONC201) is a novel agent with unknown potential for teratogenic or abortifacient effects.
  10. Had known -positive test on combination antiretroviral therapy.
  11. Had known history of cardiac arrhythmias including atrial fibrillation, tachyarrhythmias or bradycardia, unless arrhythmia is controlled and after Cardiology has cleared patient to receive dordaviprone (ONC201). Receiving therapeutic agents known to prolong will be excluded. History of congested heart failure (CHF), or myocardial infarction (MI) or stroke in the last 3 months will be excluded.
  12. Had active illicit drug use or diagnosis of alcoholism.
  13. Had tumors with known IDH1 (isocitrate dehydrogenase 1) or known IDH2 mutations as determined by immunohistochemistry for the IDH1 R132H variant or by direct sequencing. IDH1/2-mutant gliomas have a markedly longer overall survival rate compared to those with IDH1/2-wildtype glioma (Parsons et al., 2008; Yan et al., 2009), indicating IDH1/2-mutant gliomas have a distinct natural history.
  14. Had tumors with known 1p/19q co-deletion.
  15. Had known additional that is progressing or requires active treatment within 3 years of start of study drug. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, in situ melanoma, or in situ cervical cancer that has undergone potentially curative therapy.
  16. Had any surgery (not including minor diagnostic procedures such as lymph node ) within 2 weeks of baseline disease assessments; or not fully recovered from any side effects of previous procedures. An interval of 1 week for stereotactic brain biopsy from the start of study treatment is acceptable.
  17. Had concomitant use of potent cytochrome P450 (CYP)3A4/5 inhibitors during the treatment phase of the study and within 72 hours prior to starting study drug administration.
  18. Had concomitant use of potent /5 inducers, which include enzyme inducing antiepileptic drugs (EIAEDs), during the treatment phase of the study and within 2 weeks prior to starting treatment. Concurrent dexamethasone is allowed.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
73 participants (actual)

Study arms

  • Experimental
    Arm A

    Patients received 625 mg dordaviprone (ONC201) once weekly. Arm A included patients with recurrent H3 K27M-mutant glioma including those with diffuse intrinsic pontine glioma (DIPG), primary spinal tumors, and some atypical histologies.

    Drug: Dordaviprone (ONC201)

  • Experimental
    Arm B

    Patients received 625 mg dordaviprone (ONC201) once weekly. Arm B included patients with recurrent H3 K27M-mutant glioma, but excluded patients with the following: * Primary malignant lesion located in the pons or spinal cord. * Atypical non-astrocytic histologies such as ependymoma, ganglioma and pleomorphic xanthoastrocytoma, or pilocytic astrocytoma and subependymal giant cell astrocytoma (SEGA). * Prior bevacizumab treatment of \>4 doses of \>7.5 mg/kg

    Drug: Dordaviprone (ONC201)

Interventions

  • Dordaviprone (ONC201) is a central nervous system (CNS)-penetrant, small-molecule imipridone that acts as a mitochondrial caseinolytic protease P (ClpP) agonist and a dopamine receptor D2 (DRD2) antagonist.

    Also known as: Dordaviprone

06

What researchers measure

Primary outcomes

  1. Number of Patients With Overall Response

    Quantitative thresholds for objective response by Response Assessment in Neuro-Oncology (RANO) criteria for target lesions on radiographic imaging are Complete Response (CR) is the disappearance of all target lesions; Partial Response (PR) requires a ≥50% decrease in the sum of products of perpendicular diameters of target lesions from baseline. Other considerations for RANO response include assessments of non-target lesions, corticosteroids, and performance status. The Overall Response Rate is the proportion of patients who achieve either CR or PR. Tumor assessments were conducted at 8 weeks (±1 week) following the initiation of therapy and every 8 weeks (±1 week) thereafter. All patients who received at least one dose of dordaviprone (ONC201) were included in the analysis, including patients with diffuse intrinsic pontine glioma (DIPG) or primary spinal tumors, which are historically not assessable for response using RANO-HGG criteria due to anatomical or imaging limitations.

    Time frame: From first dose of study treatment through study completion, an average of 1 year

Secondary outcomes

  1. Duration of Response (DOR)

    DOR is defined as the time from the first documented response to the earliest date of disease progression or death, whichever occurred first. Patients who had not progressed or died at the time of analysis were censored at their last adequate tumor assessment.

    Time frame: From objective response (complete response or partial response) per RANO to disease progression or death, up to 40.6 months.

07

Results

Posted Jul 28, 2025
Limitations and caveats
The Sponsor terminated this study based on the initiation of a randomized Phase 3 study of dordaviprone (ONC201) in an earlier setting; closing this study ensured enrollment would not compete with the Phase 3 study. The decision was not related to any safety concerns with dordaviprone (ONC201). At the time enrollment was halted, some treatment arms had not completed enrollment. Note: This study did not assess response using RANO 2.0, as these criteria were established after study initiation.

Participant flow

Participant flow — Overall Study
MilestoneArm AArm B
Started4330
Completed00
Not completed4330

Outcome measures

PrimaryNumber of Patients With Overall Response

Quantitative thresholds for objective response by Response Assessment in Neuro-Oncology (RANO) criteria for target lesions on radiographic imaging are Complete Response (CR) is the disappearance of all target lesions; Partial Response (PR) requires a ≥50% decrease in the sum of products of perpendicular diameters of target lesions from baseline. Other considerations for RANO response include assessments of non-target lesions, corticosteroids, and performance status. The Overall Response Rate is the proportion of patients who achieve either CR or PR. Tumor assessments were conducted at 8 weeks (±1 week) following the initiation of therapy and every 8 weeks (±1 week) thereafter. All patients who received at least one dose of dordaviprone (ONC201) were included in the analysis, including patients with diffuse intrinsic pontine glioma (DIPG) or primary spinal tumors, which are historically not assessable for response using RANO-HGG criteria due to anatomical or imaging limitations.

Time frame:
From first dose of study treatment through study completion, an average of 1 year
Reported as:
Count of participants · Participants
Number of Patients With Overall Response
ParticipantsArm AArm B
Number of Patients With Overall Response55
SecondaryDuration of Response (DOR)

DOR is defined as the time from the first documented response to the earliest date of disease progression or death, whichever occurred first. Patients who had not progressed or died at the time of analysis were censored at their last adequate tumor assessment.

Time frame:
From objective response (complete response or partial response) per RANO to disease progression or death, up to 40.6 months.
Reported as:
Median · months
Duration of Response (DOR)
monthsArm AArm B
Duration of Response (DOR)5.6 (1.9 to NA)15.0 (7.5 to NA)

Adverse events

Collected over From the time/date of initiation of study treatment through 30 days following cessation of study treatment (regardless of treatment duration), or for duration of study treatment until initiation of other anticancer therapy, whichever occurred first, up to 51 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm A33/43 (76.7%)17/43 (39.5%)42/43 (97.7%)
Arm B25/30 (83.3%)7/30 (23.3%)27/30 (90%)
Most frequent serious events
Showing 10 of 40
Most frequent serious events
EventArm AArm B
EncephalopathyNervous system disorders4/431/30
HydrocephalusNervous system disorders4/430/30
SeizureNervous system disorders0/432/30
VomitingGastrointestinal disorders2/430/30
Brain oedemaNervous system disorders2/430/30
HeadacheNervous system disorders2/430/30
EmbolismVascular disorders2/430/30
Sinus tachycardiaCardiac disorders0/431/30
DeathGeneral disorders0/431/30
PyrexiaGeneral disorders0/431/30
Most frequent other events
Showing 10 of 60
Most frequent other events
EventArm AArm B
FatigueGeneral disorders14/4313/30
NauseaGastrointestinal disorders13/435/30
HeadacheNervous system disorders10/437/30
Gait disturbanceGeneral disorders10/436/30
FallInjury, poisoning and procedural complications9/436/30
DiplopiaEye disorders2/436/30
Muscular weaknessMusculoskeletal and connective tissue disorders3/436/30
VomitingGastrointestinal disorders8/433/30
Lymphocyte count decreasedInvestigations8/430/30
Oedema peripheralGeneral disorders2/435/30

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Arm AArm BTotal
<=18 years000
Between 18 and 65 years402969
>=65 years314
Age, Continuous
Age, Continuous(years)Arm AArm BTotal
Mean38.6 (20 to 72)35.0 (21 to 66)37.1 (20 to 72)
Sex: Female, Male
Sex: Female, Male(Participants)Arm AArm BTotal
Female211233
Male221840
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm AArm BTotal
Hispanic or Latino268
Not Hispanic or Latino402363
Unknown or Not Reported112
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm AArm BTotal
American Indian or Alaska Native000
Asian404
Native Hawaiian or Other Pacific Islander000
Black or African American6410
White302151
More than one race000
Unknown or Not Reported358
Primary Tumor Location/Diagnosis
Primary Tumor Location/Diagnosis(Participants)Arm AArm BTotal
Brainstem (excluding DIPG)7310
Midline (excluding brainstem, DIPG, and spinal)262046
Non-midline178
DIPG202
Spinal707
08

Study locations

9 sites
  • University of California, San Francisco
    San Francisco, California 94143-0112, United States
  • Stanford Cancer Center
    Stanford, California 94305, United States
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
  • University of Minnesota
    Minneapolis, Minnesota 55455, United States
  • New York University School of Medicine
    New York, New York 10016, United States
  • Columbia University
    New York, New York 10032, United States
  • Levine Cancer Institute
    Charlotte, North Carolina 28204, United States
  • Hospital of the University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
09

References and documents

Publications

  • Arrillaga-Romany I, Gardner SL, Odia Y, Aguilera D, Allen JE, Batchelor T, Butowski N, Chen C, Cloughesy T, Cluster A, de Groot J, Dixit KS, Graber JJ, Haggiagi AM, Harrison RA, Kheradpour A, Kilburn LB, Kurz SC, Lu G, MacDonald TJ, Mehta M, Melemed AS, Nghiemphu PL, Ramage SC, Shonka N, Sumrall A, Tarapore RS, Taylor L, Umemura Y, Wen PY. ONC201 (Dordaviprone) in Recurrent H3 K27M-Mutant Diffuse Midline Glioma. J Clin Oncol. 2024 May 1;42(13):1542-1552. doi: 10.1200/JCO.23.01134. Epub 2024 Feb 9. PubMed 38335473 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2017 to primary completion in Dec 2022, 62 months.

Results were first posted in Jul 2025, 2 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 1, 2017
First posted
Sep 27, 2017
StartActual
Oct 30, 2017
Primary completionActual
Dec 31, 2022
CompletionActual
Jul 19, 2023
Results first posted
Jul 28, 2025
Last update
Jul 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03295396
Collaborators
Oncoceutics, Inc.
Responsible party
Sponsor
First posted
Sep 27, 2017
Start date
Oct 30, 2017
Primary completion
Dec 31, 2022
Completion
Jul 19, 2023
Results posted
Jul 28, 2025
Last update
Jul 28, 2025

Study contacts

Allen Mellemed, MD
study director · Chimerix, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dordaviprone

Start the discussion